Lumos Pharma

Deerfield led the $34 million Series B financing in Lumos Pharma. Lumos is an orphan disease company that is focused on bringing novel therapies to patients with unmet medical needs in severe, rare and genetic diseases. Its lead compound, LUM-001, is being developed to treat Creatine Transporter Deficiency (CTD).